You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 12, 2025

Claims for Patent: 10,723,730

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,723,730

Title:	Solid forms of a selective CDK4/6 inhibitor
Abstract:	This invention relates to the crystalline free base of acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one, formula (1) having improved properties, to pharmaceutical compositions and dosage forms comprising the free base, and to methods for making and using such compounds, compositions and dosage forms in the treatment of cell proliferative diseases, such as cancer.
Inventor(s):	Brian Patrick Chekal, Nathan D. Ide
Assignee:	Pfizer Corp SRL
Application Number:	US15/808,577
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,723,730
Patent Claims:	1. A crystalline free base of 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one, having a powder X-ray diffraction pattern comprising peaks at diffraction angles (2θ) of 8.0±0.2, 10.1±0.2 and 11.5±0.2 and a primary particle size distribution characterized by a D90 value of from about 30 μm to about 65 μm. 2. The free base of claim 1, having a powder X-ray diffraction pattern comprising peaks at diffraction angles (2θ) of 8.0±0.2, 10.1±0.2, 10.3±0.2, and 11.5±0.2. 3. The free base of claim 1, having a powder X-ray diffraction pattern comprising peaks at diffraction angles (2θ) essentially the same as shown in FIG. 1. 4. The free base of claim 1, having a 13C solid state NMR spectrum comprising the following resonance (ppm) values: 12.5 ppm±0.2 ppm. 5. The free base of claim 4, having a 13C solid state NMR spectrum comprising the following resonance (ppm) values: 12.5 ppm and 112.4 ppm±0.2 ppm. 6. The free base of claim 5, having a 13C solid state NMR spectrum comprising the following resonance (ppm) values: 12.5 ppm, 112.4 ppm and 143.2 ppm±0.2 ppm. 7. A crystalline free base of 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one, having a powder X-ray diffraction pattern comprising peaks at diffraction angles (2θ) of 8.0±0.2, 10.1±0.2 and 11.5±0.2 and a volume mean diameter characterized by a D[4,3] value of from about 15 μm to about 40 μm. 8. The free base of claim 7, having a powder X-ray diffraction pattern comprising peaks at diffraction angles (2θ) of 8.0±0.2, 10.1±0.2, 10.3±0.2, and 11.5±0.2. 9. The free base of claim 7, having a powder X-ray diffraction pattern comprising peaks at diffraction angles (2θ) essentially the same as shown in FIG. 1. 10. The free base of claim 7, having a 13C solid state NMR spectrum comprising the following resonance (ppm) values: 12.5 ppm±0.2 ppm. 11. The free base of claim 10, having a 13C solid state NMR spectrum comprising the following resonance (ppm) values: 12.5 ppm and 112.4 ppm±0.2 ppm. 12. The free base of claim 11, having a 13C solid state NMR spectrum comprising the following resonance (ppm) values: 12.5 ppm, 112.4 ppm and 143.2 ppm±0.2 ppm. 13. A pharmaceutical composition comprising the free base of claim 1 and at least one pharmaceutically acceptable carrier, diluent or excipient. 14. A pharmaceutical composition comprising the free base of claim 7 and at least one pharmaceutically acceptable carrier, diluent or excipient. 15. A crystalline free base of 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one, having a powder X-ray diffraction pattern comprising peaks at diffraction angles (2θ) of 8.0±0.2, 10.1±0.2 and 11.5±0.2 and a volume mean diameter characterized by a D[4,3] value of from about 15 μm to about 30 μm. 16. The free base of claim 15, having a powder X-ray diffraction pattern comprising peaks at diffraction angles (2θ) of 8.0±0.2, 10.1±0.2, 10.3±0.2, and 11.5±0.2. 17. The free base of claim 15, having a powder X-ray diffraction pattern comprising peaks at diffraction angles (2θ) essentially the same as shown in FIG. 1. 18. The free base of claim 15, having a 13C solid state NMR spectrum comprising the following resonance (ppm) values: 12.5 ppm±0.2 ppm. 19. The free base of claim 18, having a 13C solid state NMR spectrum comprising the following resonance (ppm) values: 12.5 ppm and 112.4 ppm±0.2 ppm. 20. The free base of claim 19, having a 13C solid state NMR spectrum comprising the following resonance (ppm) values: 12.5 ppm, 112.4 ppm and 143.2 ppm±0.2 ppm. 21. A pharmaceutical composition comprising the free base of claim 15 and at least one pharmaceutically acceptable carrier, diluent or excipient.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.